Abstract 246P
Background
First-line (1L) platinum-based chemotherapy (CT) improves survival in metastatic urothelial cancer (mUC). Cisplatin eligibility for pivotal clinical trials excludes renal impairment (eGFR≤60mL/min). Impact of renal impairment on prescribing in the real world is unknown.
Methods
A cohort of mUC patients (pts) having 1L CT was extracted from BLADDA, Australia’s multisite, urothelial cancer registry. Clinicodemographic and outcome data were analysed using descriptive statistics. Statistical significance was defined by p≤0.05. Progression-free (PFS) and overall (OS) survival was defined as time to progression or death from 1L CT.
Results
Our cohort included 132 pts, median age 70 (range 29-86), predominantly male (76%), ECOG 0-1 (88%) and de novo metastatic (58%). Renal function was known in 104 pts; 47% had eGFR≤60 (eGFR 40-60: 34%; eGFR≤40: 13%). Most pts received 1L platinum-based CT (76%). In pts without renal impairment (eGFR>60), carboplatin/gemcitabine was more common than cisplatin/gemcitabine (GC) (40% vs 31%, p=0.3). In pts with renal impairment (eGFR ≤60), carboplatin/gemcitabine remained the most common (33%), followed by GC (18%) and split dose GC (18%). Renal function did not predict cisplatin use (>60: 38% vs ≤60: 37%; OR 1.1, p=0.9), nor impact trial enrolment (>60: 6% vs ≤60: 12%; OR 0.4, p=0.2). Dose reductions were numerically more common in renal impairment (>60: 35% vs ≤60: 49%; OR 2, p=0.2). Renal impairment did not impact response rate (>60: 65% vs ≤60: 68%; p=0.8) but resulted in shorter PFS (14 months, 95% CI 9-19 vs 7, 95% CI 6-8) and OS (37 months, 95% CI 29-NE vs 27, 95% CI 22-33). Table: 246P
All patients (n=132) | eGFR known at 1L treatment (n= 104) | |||
>60 (n= 55) (%) | <60 (n =49) | |||
40-60 (n=35) (%) | <40 (n=14) (%) | |||
1L treatment – Cisplatin-based GC GC (split dose) MVAC/ddMVAC Carboplatin/gemcitabineTrialPembrolizumabOther | 47 (36) 33 (25) 10 (8) 4 (3) 50 (38)11 (8)14 (11)10 (8) | 21 (38) 16 (29) 1 (2) 4 (7) 22 (40)3 (6)7 (13)2 (4) | 11 (31) 6 (17) 5 (14) 0 13 (37)6 (17)3 (9)2 (6) | 7 (50) 3 (21) 4 (29) 0 3 (21)001 (7) |
Median PFS– months (95%CI) | 9 (6-11) | 14 (9-19) | 7 (6-8) | 7 (4-9) |
Median OS – months (95%CI) | 28.8 (21-37) | 37 (29-NE) | 29 (13-45) | 24 (23-25) |
Conclusions
In this real-world analysis, pts receiving 1L CT with impaired renal function had inferior PFS and shortened OS, which was not explained by differences in cisplatin use. Our study is limited by few pts with eGFR<40 and did not evaluate those unfit for CT. Further research to determine optimal 1L therapy in this cohort is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, BMS, Pfizer, Merck.
Disclosure
A.J. Weickhardt: Financial Interests, Personal, Advisory Board: Merck, Ipsen, Pfizer; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Coordinating PI, PCR MIB funding: Merck. P. Gibbs: Financial Interests, Personal, Advisory Board: Merck, Bayer, Amgen, Servier, Haystack Oncology; Financial Interests, Personal, Invited Speaker: MSD. B. Tran: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Astellas, Bayer, BMS, Ipsen, IQVIA, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Tolmar, Sanofi Ammunix; Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BMS, Merck, Pfizer; Financial Interests, Institutional, Research Grant: Amgen, Astellas, AstraZeneca, Bayer, BMS, Genentech, Ipsen, Janssen, Pfizer, MSD; Financial Interests, Personal, Steering Committee Member: CG Oncology, Janssen, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract